10.21
Schlusskurs vom Vortag:
$10.51
Offen:
$10.75
24-Stunden-Volumen:
81,639
Relative Volume:
0.38
Marktkapitalisierung:
$60.53M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.3964
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
+13.74%
1M Leistung:
-40.06%
6M Leistung:
+35.39%
1J Leistung:
-59.23%
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4244
Adresse
2380 CONEJO SPECTRUM ST, THOUSAND OAKS, CA
Vergleichen Sie ATRA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ATRA
Atara Biotherapeutics Inc
|
10.30 | 60.53M | 100.44M | -133.16M | -94.85M | -25.76 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
473.66 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
716.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
653.67 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
275.27 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
119.20 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-07-13 | Herabstufung | Stifel | Buy → Hold |
2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
2019-05-30 | Eingeleitet | ROTH Capital | Buy |
2019-05-23 | Eingeleitet | Stifel | Buy |
2019-01-23 | Eingeleitet | Mizuho | Buy |
2018-04-10 | Eingeleitet | JP Morgan | Overweight |
2018-03-16 | Eingeleitet | Guggenheim | Neutral |
2018-03-05 | Bestätigt | Jefferies | Buy |
2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation - Markets Insider
Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Price Target at $17.75 - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - Markets Insider
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Wolf Haldenstein Adler Freeman & Herz LLP announces that it - GlobeNewswire
2025-02-03 | Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
2025-02-02 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect | NDAQ:ATRA | Press Release - Stockhouse Publishing
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
2025-01-31 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
Layoff Tracker: Rentschler’s Cell and Gene Therapy Exit Could Affect Up to 30 - BioSpace
HC Wainwright Issues Positive Outlook for ATRA Earnings - Defense World
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - GlobeNewswire Inc.
(ATRA) Investment Analysis - Stock Traders Daily
2025-01-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation - Markets Insider
HC Wainwright Reaffirms Neutral Rating for Atara Biotherapeutics (NASDAQ:ATRA) - Defense World
Q3 EPS Forecast for Atara Biotherapeutics Lifted by Analyst - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out - Markets Insider
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - PR Newswire
Atara stock holds Neutral rating after workforce cut - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out - Markets Insider
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - The Malaysian Reserve
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect - Markets Insider
Atara reduction in workforce to impact 50% of current employees - MSN
2025-01-27 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect | NDAQ:ATRA | Press Release - Stockhouse Publishing
Atara Biotherapeutics Sees Its Share Price Fall - San Fernando Valley Business Journal
Atara to cut 50% of workforce amid FDA woes - MSN
Atara to cut 50% of workforce amid FDA woes (ATRA:NASDAQ) - Seeking Alpha
Atara Biotherapeutics’ (ATRA) “Neutral” Rating Reiterated at HC Wainwright - Defense World
What is HC Wainwright’s Forecast for ATRA FY2024 Earnings? - Defense World
Stifel cuts Atara Biotherapeutics target to $5, holds rating - MSN
Atara Biotherapeutics (NASDAQ:ATRA) Cut to Hold at RODMAN&RENSHAW - Defense World
Atara extends losses after FDA clinical hold - MSN
Clinical hold follows CRL for Atara - The Pharma Letter
Atara Biotherapeutics stock hits 52-week low at $6.4 amid challenges - Investing.com
Atara, Already Slapped With CRL, Gets A Clinical Hold As Well - News & Insights
Stifel cuts Atara Biotherapeutics target to $5, holds rating By Investing.com - Investing.com UK
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs - AOL
US FDA puts clinical hold on Atara's trials for cancer cell therapies - Reuters
Atara stock extends losses on FDA clinical hold (ATRA:NASDAQ) - Seeking Alpha
Atara's New Drug Applications Placed on Hold by FDA - MarketWatch
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219 - Business Wire
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate - MSN
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues - Seeking Alpha
Trend Tracker for (ATRA) - Stock Traders Daily
Canaccord Genuity Group Issues Pessimistic Forecast for Atara Biotherapeutics (NASDAQ:ATRA) Stock Price - Defense World
Atara stock plummets on FDA setback for EBV drug - MSN
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atara Biotherapeutics Inc-Aktie (ATRA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Hyllengren Eric J | EVP, CFO and COO |
Nov 18 '24 |
Sale |
11.20 |
1,364 |
15,274 |
23,392 |
Nguyen AnhCo | President and CEO |
Nov 18 '24 |
Sale |
11.20 |
1,664 |
18,633 |
77,454 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):